Michael Friedlander
A5021894535- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Endometrial and Cervical Cancer Treatments
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Reproductive Biology and Fertility
- Cancer Risks and Factors
- Renal cell carcinoma treatment
- Intraperitoneal and Appendiceal Malignancies
- DNA Repair Mechanisms
- Childhood Cancer Survivors' Quality of Life
- Testicular diseases and treatments
- Advanced Breast Cancer Therapies
- Global Cancer Incidence and Screening
- Nutrition, Genetics, and Disease
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Economic and Financial Impacts of Cancer
Prince of Wales Hospital
2016-2025
UNSW Sydney
2016-2025
Australia New Zealand Gynaecological Oncology Group
2013-2024
Royal Hospital for Women
2014-2024
The University of Melbourne
2006-2024
Prince of Wales Hospital
1982-2023
Institute of Cancer Research
2013-2023
Medical College of Wisconsin
2023
Dana-Farber Cancer Institute
2009-2023
Cancer Research UK
2013-2023
<h3>Importance</h3> The clinical management of<i>BRCA1</i>and<i>BRCA2</i>mutation carriers requires accurate, prospective cancer risk estimates. <h3>Objectives</h3> To estimate age-specific risks of breast, ovarian, and contralateral breast for mutation to evaluate modification by family history location. <h3>Design, Setting, Participants</h3> Prospective cohort study 6036<i>BRCA1</i>and 3820<i>BRCA2</i>female (5046 unaffected 4810 with or ovarian both at baseline) recruited in 1997-2011...
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but as maintenance therapy is uncertain.
A method has been developed that allows flow cytometry to be used for measuring the cellular DNA content of paraffin-embedded human tumors. Thick (i.e., 30 micron) sections were cut from tissue blocks using a microtome and dewaxed in xylene. The then rehydrated by sequentially immersing them 100, 95, 70, 50% ethanol before finally washing distilled water. Single cell suspensions prepared incubation 0.5% pepsin, pH 1.5, at 37 degrees C min. cells counted, washed, stained with 1 microgram/ml...
Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer or without BRCA1 BRCA2 germline mutations.We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment olaparib platinum-sensitive, relapsed, who had received two more platinum-based regimens and partial complete response their most recent regimen. Patients were randomly...
Purpose Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) –associated breast ovarian cancers. We evaluated the efficacy safety of olaparib a spectrum BRCA1/2-associated Patients Methods This multicenter phase II study enrolled individuals BRCA1/2 mutation recurrent cancer. Eligibility included cancer resistant to prior platinum; ≥ three chemotherapy regimens for metastatic disease; pancreatic gemcitabine treatment; or prostate...
The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. impact mutation on response requires further investigation understand its treatment planning clinical trial design.Women nonmucinous carcinoma (n = 1,001) enrolled onto a population-based, case-control study were screened for point large deletions both genes. Survival outcomes responses multiple lines chemotherapy assessed.Germ-line found 14.1% patients overall,...
Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance initial treatment patients high-grade serous ovarian carcinoma. In an international, phase 3, placebo-controlled trial, we assessed efficacy veliparib added to first-line induction carboplatin and paclitaxel continued monotherapy previously untreated stage III or IV Patients were randomly assigned a 1:1:1 ratio...
To determine if incorporation of an additional cytotoxic agent improves overall survival (OS) and progression-free (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) primary peritoneal who receive carboplatin paclitaxel.
The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well response treatment recurrent disease using serum marker CA 125 and specified situations where these used. However, publications did not include detailed definitions, nor were they written accommodate new version of Response Evaluation Criteria In Solid Tumors (RECIST) (version...
Purpose Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy nonrandomized phase II trials patients with ovarian cancer BRCA1 BRCA2 deficiency. We assessed the comparative and safety of olaparib pegylated liposomal doxorubicin (PLD) this patient population. Patients Methods In multicenter, open-label, randomized, study, recurred within 12 months prior platinum...
By using a recently developed flow cytometric method we have analyzed cellular DNA content of paraffin-embedded histological material from cancer patients. This allows the retrospective study tumors patients whose clinical outcome is already known, and applied it to ovarian cancers, stage II breast metastatic adenocarcinoma unknown primary site. In addition knowledge patient survival, comprehensive information was available about other prognostic determinants treatment received, used...